Positive CHMP opinion on first-in-class medicine to treat pulmonary arterial hypertension

View source ↗

Summary

The European Medicines Agency's CHMP issued a positive opinion for Winrevair, a first-in-class medicine for pulmonary arterial hypertension, potentially enablin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• WINREVAIR (SOTATERCEPT-CSRK)

Snippet

Winrevair received support through PRIority Medicines (PRIME) scheme due to its potential to bring a major therapeutic advantage over existing therapies